| Name | Title | Contact Details |
|---|
Dauterman Medical is a Aiea, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Noridian Healthcare Solutions, LLC (Noridian) develops solutions for federal, state and commercial health care programs through a full suite of innovative offerings, including claims processing, medical review, and contact center and provider administrative services. Headquartered in Fargo, N.D. with staff located throughout the nation, Noridian administrates people-first services across all 50 U.S. states. Leveraging its decades of experience, the Noridian team designs and implements customizable, high-quality solutions to eliminate common health care barriers, enabling access to care.
Founded in 1987, Health Level Seven (HL7) is an ANSI-accredited non-profit that empowers global health data interoperability by developing standards and enabling their adoption and implementation – for a world where everyone can securely access and use the right health data when and where they need it.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Air Force Insurance Fund is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.